Bruce S. Lavin
Bruce S. Lavin has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Christine Soufflet
Necker-Sainte Anne Hospital, Paris, France
1 shared publicationDamien Colas
Bioserenity SMS, Paris, France
1 shared publication- Hervé Vespignani
Lorraine University, Vandoeuvre-les-, Nancy, France
1 shared publication J Ross Maclean
Precision Health Economics, Los Angeles, CA, USA
1 shared publication- Jacquelyn W. Chou
PRECISIONheor , Bethesda , United States of America
1 shared publication - Louis Maillard
Video‐Electroencephalographic Monitoring Unit, Department of Neurology Central Hospital, Nancy Regional University Hospital Center Nancy France
1 shared publication
Latest Publications
- Open Access
- 13 June 2020
- Published by Wiley in Annals of Neurology
- Vol. 88 (3) , 626-630
Report on Electroencephalographic Findings in Critically Ill Patients with COVID‐19
In March 2020, we treated a cohort of 26 critically ill hospitalized SARS‐CoV‐2–infected patients who underwent electroencephalography to assess unexplained altered mental status, loss of consciousness, or poor arousal and responsiveness. Of the 26 patients studied, 5 patients had electroencephalograms that showed periodic discharges consisting of high‐amplitude frontal monomorphic delta waves with absence of epileptic activity. These findings may suggest central nervous system injury potentially related to COVID‐19 in these patients. ANN NEUROL 2020;88:626–630
- 13 June 2020
- Published by Wiley in Annals of Neurology
- Vol. 88 (3) , 626-630
Open AccessReport on Electroencephalographic Findings in Critically Ill Patients with COVID‐19
In March 2020, we treated a cohort of 26 critically ill hospitalized SARS‐CoV‐2–infected patients who underwent electroencephalography to assess unexplained altered mental status, loss of consciousness, or poor arousal and responsiveness. Of the 26 patients studied, 5 patients had electroencephalograms that showed periodic discharges consisting of high‐amplitude frontal monomorphic delta waves with absence of epileptic activity. These findings may suggest central nervous system injury potentially related to COVID‐19 in these patients. ANN NEUROL 2020;88:626–630
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Research and Reviews in Parkinsonism
- Vol. ume 10, 1-6
Challenges and Opportunities in Atypical Parkinsonian Syndromes: Call to Action
Neurodegenerative diseases are a leading cause of disability and death in the United States, and the burden of rare neurodegenerative conditions such as atypical Parkinsonian syndromes is expected to grow in the coming years as the size of the older population increases at an unprecedented rate. Atypical Parkinsonian syndromes encompass a collective of rare neurodegenerative diseases that are often misdiagnosed as Parkinson’s disease due to similar signs and symptoms. These syndromes include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD), and are characterized by rapid disease progression and decreased life expectancy. In this paper, we describe the substantial burden atypical Parkinsonian syndromes pose to the healthcare system and patients attributable to challenges in diagnosis, ineffective treatment options, and rapid functional decline. Despite increased understanding and recognition of these disorders, there remains significant unmet need for patients with atypical Parkinsonian syndromes. We provide recommendations to policymakers to support access to effective disease management of atypical Parkinsonian syndromes through legislative efforts that i) prioritize development of disease-modifying treatments, ii) focus on objectively assessing disease progression in addition to symptom management, and iii) bring forth economic frameworks that capture the full value of treatments.
- 1 January 2020
- Published by Taylor & Francis in Research and Reviews in Parkinsonism
- Vol. ume 10, 1-6
Open AccessChallenges and Opportunities in Atypical Parkinsonian Syndromes: Call to Action
Neurodegenerative diseases are a leading cause of disability and death in the United States, and the burden of rare neurodegenerative conditions such as atypical Parkinsonian syndromes is expected to grow in the coming years as the size of the older population increases at an unprecedented rate. Atypical Parkinsonian syndromes encompass a collective of rare neurodegenerative diseases that are often misdiagnosed as Parkinson’s disease due to similar signs and symptoms. These syndromes include progressive supranuclear palsy (PSP), multiple system atrophy (MSA), and corticobasal degeneration (CBD), and are characterized by rapid disease progression and decreased life expectancy. In this paper, we describe the substantial burden atypical Parkinsonian syndromes pose to the healthcare system and patients attributable to challenges in diagnosis, ineffective treatment options, and rapid functional decline. Despite increased understanding and recognition of these disorders, there remains significant unmet need for patients with atypical Parkinsonian syndromes. We provide recommendations to policymakers to support access to effective disease management of atypical Parkinsonian syndromes through legislative efforts that i) prioritize development of disease-modifying treatments, ii) focus on objectively assessing disease progression in addition to symptom management, and iii) bring forth economic frameworks that capture the full value of treatments.